SKILLMAN, N.J. - Kenvue Inc . (NYSE: NYSE:KVUE), known as the world's largest consumer health company by revenue, announced the launch of its Neutrogena® Collagen Bank™, a new skincare line featuring patented micro-peptide technology. The products are designed to support skin's natural collagen and target the pre-aging market, with a focus on Gen Z consumers.
The Neutrogena® Collagen Bank™ utilizes a micro-peptide formula that is claimed to be two times smaller than the leading anti-aging peptides, allowing it to penetrate more than 10 layers under the skin's surface. Developed with dermatologists, this technology aims at five key markers for maintaining the skin's firming support matrix: elastin, pro-collagen, hyaluronic acid, fibronectin, and decorin.
The product line includes two moisturizers. The first contains bakuchiol, a plant-based alternative to retinol, designed to defend against collagen-damaging factors and reduce visible signs of early skin aging. The second is a broad spectrum SPF 30 moisturizer, intended to protect against sun damage, a major factor in collagen depletion. When used in tandem, the products are clinically proven to address five early signs of collagen decline and diminish fine lines and wrinkles, with the aim of providing plumper-looking skin.
In a strategic move to appeal to the digitally savvy Gen Z demographic, Neutrogena® initially launched the collection exclusively on TikTok Shop in July, before making it available through traditional retailers such as Amazon (NASDAQ:AMZN), Ulta Beauty (NASDAQ:ULTA), Walmart (NYSE:WMT), and Target.
Kenvue emphasizes that Neutrogena® Collagen Bank™ offers an affordable and accessible option compared to in-office treatments and other high-priced products in the market. The line is currently available for purchase online and at mass retailers nationwide.
The press release from Kenvue also includes cautionary language regarding forward-looking statements, advising readers to not rely solely on these projections, as actual results may differ due to various risks and uncertainties.
This news article is based on a press release statement from Kenvue Inc.
In other recent news, Kenvue, a global leader in health and beauty products, reported a modest organic growth of 1.5% year-over-year and a significant increase in adjusted gross profit margin to 61.6% in its second-quarter earnings call for 2024. The company announced an increase in dividends, indicating confidence in its long-term strategy for shareholder value creation. Despite volume declines in the Self Care and Skin Health and Beauty segments, Kenvue is on track to meet its financial targets for the year, with plans to increase brand investments by up to $100 million.
The company anticipates a full-year adjusted operating margin of 21% to 22% and expects to deliver within the sales and EPS outlook ranges for 2024. Notably, Kenvue is investing in high-yield strategies, including healthcare professional and direct consumer engagement, and expects to achieve attractive total shareholder return in 2025 and beyond.
Despite challenges in the dermatological side of the Skin Health category, the Essential Health segment exhibited strong organic growth across all categories and regions. Furthermore, the company has seen share gains in the flat-growth Self Care segment and expects positive growth in China for this segment. These recent developments suggest Kenvue's strategic focus on brand investment and operational efficiency is yielding results.
InvestingPro Insights
As Kenvue Inc. (NYSE: KVUE) launches its innovative Neutrogena® Collagen Bank™ line, the company's financial health and market performance offer insights into its capacity to support and market new ventures. According to the latest metrics from InvestingPro, Kenvue boasts a robust gross profit margin of 57.51% over the last twelve months as of Q2 2024. This impressive margin highlights the company's efficiency in managing its production costs and its ability to retain a significant portion of revenue after accounting for the cost of goods sold, which is crucial for funding new product development and marketing strategies.
InvestingPro Tips also indicate that analysts predict Kenvue will be profitable this year, complementing the company's strong return over the last month with an 18.09% price total return. This suggests that investors have a positive outlook on the company's financial prospects, including the potential success of its latest skincare line targeting the pre-aging market. The market cap of Kenvue stands at an adjusted $40.56 billion, reflecting a substantial valuation that underscores its position as a leading player in the consumer health sector.
For those interested in a deeper analysis of Kenvue's financial outlook, InvestingPro provides additional tips and data. There are currently six more InvestingPro Tips available, offering further insights into the company's earnings revisions, debt levels, and earnings multiples. Visit the dedicated Kenvue page at https://www.investing.com/pro/KVUE for more exclusive information.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.